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Case Report 
Bullous Cellulitis Caused by Serratia marcescens 
Curtis L. Cooper, MD;* Marni Wiseman, MD;* and Robert Brunham, MD*+ 
Bullous cellulitis is a distinctive form of cellulitis most 
often caused by beta hemolytic streptococci. This report 
describes a case of bullous cellulitis caused by Serratia 
marcescens in an elderly diabetic woman with peripheral 
vascular disease. A discussion of this ubiquitous, noso- 
comial pathogen follows. 
CASE REPORT 
A 69;year-old First Nations female with type II diabetes 
mellitus, coronary artery disease, and peripheral vascu- 
lar disease presented to a northern medical station fol- 
lowing a l-week history of pain and erythema of her left 
foot that was associated with fever and chills. Forty-eight 
hours after onset of the fever, two large, purple bullae 
developed in the area of cellulitis on the dorsum of the 
left foot and the anterior surface of the distal left leg. At 
that time, empirical treatment with intravenous clin- 
damycin and gentamicin was initiated. The patient denied 
further fever; however, she continued to experience sig- 
nificant discomfort in her left foot. This pain was par- 
tially relieved with dependency of the foot. Concerns 
over poor response to therapy prompted transfer to the 
Health Sciences Centre, Winnipeg. Past pertinent med- 
ical history included removal of an ingrown and chroni- 
cally infected left great toenail 1 month prior to 
presentation. The patient received no perioperative 
antimicrobial therapy; however, she did soak her toe in 
chlorhexadine, an antiseptic solution. Additionally, she 
complained of intermittent claudication of both her 
calves, but denied rest pain. She did not have a past his- 
tory of diabetic foot ulcers. 
Upon presentation, the patient was not in distress, but 
complained of prominent left foot pain. Examination of 
the left limb revealed two tense, purple bullae, each mea- 
suring approximately 10 X 15 cm (Figure 1). One was 
located on the dorsum of the foot and the other on the dis 
tal medial ankle. A limited area of cellulitis surrounded the 
bullae. The base of the bullae was erythematous. This 
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region was not purulent or foul smelling. Neither crepitus 
nor lymphangitis was noted. The great toenail was absent. 
The foot was cool to palpation, with diminished pulses 
distal to the popliteal artery. Mild pedal edema was present 
bilaterally. Laboratory examination revealed a leukocyte 
count 17.1 X 109/L with a left shift of 7%, and an ery- 
throcyte sedimentation rate of 99 mL/hr. A femoral 
angiogram revealed extensive peripheral vascular disease 
with diminished blood flow distal to the popliteal artery 
and no evidence of arterial thrombosis. Lower limb pres- 
sure studies of the left leg indicated severe obstruction, 
with low distal perfusion and a halluxbrachial systolic 
pressure index of 0.14. Studies of the right lower limb indi- 
cated only moderate obstruction of blood flow in the main 
arteries with good distal perfusion and a ratio of .53. 
Doppler ultrasound did not reveal a deep vein thrombo- 
sis and radiography did not demonstrate any bony abnor- 
malities. Blood cultures were negative. Low viscosity, 
translucent, red-colored fluid was aspirated from both bul- 
lae. Gram stain of the fluid revealed 10 polymorphic leuko- 
cytes per high-power field and 10 to 100 gram-negative 
bacilli per high-power field. No red blood cells were noted. 
The sole organism isolated after aerobic and anaerobic cul- 
ture from both bullae was S. marcescens. The antibiogram 
indicted resistance to ampicillin (MIC >16 pg/mL), cefa- 
zolin (MIC >16 pg/mL), and cefuroxime (MIC >16 ug/mL). 
The organism was sensitive to third generation 
cephalosporins, aminoglycosides, and ciprofloxacin (MIC 
< 1 pg/mL). Following identification of S. marcescens the 
patient was started on a IO-day course of ciprofloxacin. 
Resolution of the cellulitis began at day 7 of treatment, 
and the patient was discharged to the northern medical sta- 
tion. At the northern medical station, it was noted that 
despite antimicrobial therapy and meticulous wound care, 
the left ankle became progressively ischemic and ultimately 
progressed to vascular gangrene. The patient underwent a 
left below knee amputation 1 month after her discharge 
from the Health Services Centre. Her postoperative course 
was uncomplicated. 
DISCUSSION 
Bullous cellulitis occurs most often with beta hemolytic 
streptococci (Streptococcus pyogenes) infection and less 
commonly with infection due to Staphylococcus aureus. 
Secondary bullous cellulitis complicating gram-negative 
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Figure 1. Examination of the left foot revealed tense, purole bullae, measuring approximately 10 X 15 cm on the distal medial ankle (left) and 
on the dorsum (right). 
bacteremia rarely has been documented. Organisms 
isolated include Pseudomonas aeruginosa, Escberichia 
coli, Aeromonas hydrophila, Morganella morganii, 
Enterobacter cloacae, Vibrio vulnajiicus, and Salmonella 
enteritidis.‘-’ Primary cases due to the above organisms 
have not been documented. To the authors’ knowledge, 
S. marcescens previously has been associated with bullous 
cellulitis in a single case report.’ This patient was an 
immunocompromised male who developed a polymi- 
crobial infection at the site of a biopsy. The present case 
is the first report of bullous cellulitis caused solely by S. 
marcescens. This association is supported by the fact that 
S. marcescens alone was isolated from three separate aspi- 
rations. The combination of fever, local discomfort, appear- 
ance of the region surrounding the bullae, and the Gram 
stain suggest that infection, rather than colonization, was 
present. The patient’s stable clinical presentation and neg- 
ative blood cultures suggest that the bullous cellulitis was 
primary and not secondary to bacteremic seeding of S. 
marcescens from another source. 
Risk factors for infection with S. marcescens include 
chronic debilitating disease, diabetes mellitus, cortico- 
steroid use, recent therapy with broad-spectrum antibi- 
otics, indwelling catheters, mechanical ventilation, and 
tracheostomy’ This patient had had diabetes for over 20 
years and had been on antibiotics for cellulitis of the left 
great toe 1 month previously. 
Serratia marcescens is a ubiquitous organism found 
in both soil and water environments. Its ecology in moist 
environments results in its frequent isolation as a conta- 
minant of ventilation equipment, tracheostomy tubes, and 
indwelling catheters. Without appropriate precautions, 
normally sterile hospital solutions can become contami- 
nated with this organism. Potential sources of infection 
include peritoneal dialysis fluid, enteral feeling solutions, 
and antiseptic solutions. lo-l3 Serratia marcescens cel- 
lulitis has been reported in a patient on hemodialysis that 
was presumed to be secondary to dialysate contamina- 
tion.‘* In the present case, the patient gave a history of 
soaking her ingrown great toe in chlorhexidine antisep- 
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tic solution approximately 3 weeks prior to her presen- 
tation with bullous cellulitis. It is speculated that her col- 
onization and subsequent infection may have been 
attributable to contamination of her antiseptic solution. 
Unfortunately, the antiseptic solution could not be 
obtained for culture. Interestingly, S. marcescens is known 
to be resistant to chlorhexidine.12 
Multidrug resistance is a well-known feature of S. mar- 
cescens. Serratia possesses a chromosomal B-lactamase 
that necessitates high concentrations of B-lactamase 
inhibitors to achieve bacteriocidal levels.15 Quinolone 
resistance has been attributed to outer membrane protein 
alterations that result in diminished antibiotic perme- 
ability. l6 Aminoglycoside resistance also has been 
reported. Both aminoglycosides and third generation 
cephalosporins are regarded as first line therapy for Ser- 
ratia infections.17a1s Oral ciprofloxacin is also recom- 
mended for serious soft tissue infections caused by this 
organism.r9 The patient presented here was initially 
treated with gentamicin, resulting in resolution of her 
fever and chills. Subsequently, the gentamicin was dis- 
continued and therapy with oral ciprofloxacin was initi- 
ated to complete a therapeutic course of 14 days. This 
decision was guided by the patient’s overall satisfactory 
condition, the antibiogram profile of the organism, and 
the advantages of an oral route of administration. 
The diagnostic differential of bullous cellulitis is 
broad. To the authors’ knowledge, this patient represents 
the first case report of bullous cellulitis caused solely by 
S. marcescens. It is postulated that her exposure to the 
organism occurred while she soaked her foot in a cont- 
aminated antiseptic solution. Diabetes and recent antibi- 
otic use were additional contributing risk factors. 
Empirical therapy with gentamicin, followed by 
ciprofloxacin resulted in resolution of the bullous cel- 
lulitis, however, vascular compromise of the leg necessi- 
tated subsequent amputation despite successful initial 
treatment. 
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